Here’s an interesting tidbit that I came across:
A new study, to be published in a forthcoming issue of the Journal of Political Economy, calculates the prospective gains that could be obtained from further progress against major diseases. Kevin M. Murphy and Robert H. Topel, two University of Chicago researchers, estimate that even modest advancements against major diseases would have a significant impact � a 1 percent reduction in mortality from cancer has a value to Americans of nearly $500 billion. A cure for cancer would be worth about $50 trillion.
“We distinguish two types of health improvements � those that extend life and those that raise the quality of life,” explain the authors. “As the population grows, as incomes grow, and as the baby-boom generation approaches the primary ages of disease-related death, the social value of improvements in health will continue to rise.”
Many critiques of rising medical expenditures focus on life-extending procedures for persons near death. By breaking down net gains by age and gender, Murphy and Topel show that the value of increased longevity far exceeds rising medical expenditures overall. Gains in life expectancy over the last century were worth about $1.2 million per person to the current population, with the largest gains at birth and young age.
“An analysis of the value of health improvements is a first step toward evaluating the social returns to medical research and health-augmenting innovations,” write the authors. “Improvements in life expectancy raise willingness to pay for further health improvements by increasing the value of remaining life.”
I can’t comment on the methodology, but, if accurate, it gives an idea of just what a toll cancer takes not just in human suffering, but in the economy.